2096 — Simcere Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$27.27bn
- HK$24.00bn
- CNY7.73bn
Brief: Simcere Pharmaceutical Says SIM0610 Receives Clinical Trial Approval From NMPA China
Brief: Simcere Pharmaceutical Enters Exclusive Licensing Agreement With Ipsen
Simcere climbs on license deal with Vigonvita
Brief: Vigonvita Life Sciences Co Enters License Agreement With Simcere For Vv116
Brief: Simcere Pharmaceutical Obtains Exclusive Rights For RSV And HMPV Treatment
Brief: NextCure And Simcere Zaiming Announce Expansion Of Ongoing Phase 1 Trial Of SIM0505 Into The US
Brief: Simcere Pharmaceutical Group Says SIM0609 Obtains Clinical Trial Approval In China By NMPA
Brief: Simcere Pharmaceutical Says NDA Of Deunoxavir Marboxil Accepted By China's NMPA
Simcere Pharmaceutical falls most in 2-1/2 months on discounted share sale
Brief: Simcere Pharmaceutical To Issue 121 Million Subscription Shares
Brief: Simcere Pharmaceutical Says Unit To Buy Entire Assets Of Sanroad Shanghai For RMB17.5 Mln
Brief: Simcere Pharmaceutical Posts H1 Revenue Of RMB 3,585 Million
Brief: Simcere Pharmaceutical To Repurchase Shares Up To RMB500 Mln
Brief: Simcere Pharmaceutical Says New Drug Application Of Rademikibart Was Accepted By China's NMPA
Brief: Simcere Pharmaceutical Announces Approval For Marketing Of Enzeshu In China By NMPA
Brief: Simcere Pharmaceutical Says Approval For Marketing Of Quviviq ® In China By NMPA
NextCure signs up to $745 million deal with China's Simcere to develop cancer drug
Brief: Simcere Pharmaceutical's Unit Enters Into License Agreement With Nextcure
Brief: Nextcure And Simcere Zaiming Announce Strategic Partnership For A Novel Antibody-Drug Conjugate Targeting CDH6